{"id":"NCT00102440","sponsor":"Takeda","briefTitle":"Febuxostat Versus Allopurinol Control Trial in Subjects With Gout","officialTitle":"A Phase 3, Randomized, Multicenter Study Comparing the Safety and Efficacy of Oral Febuxostat Versus Allopurinol in Subjects With Gout","status":"COMPLETED","phase":"PHASE3","dates":{"start":"2002-07","primaryCompletion":"2004-02","completion":"2004-02","firstPosted":"2005-01-31","resultsPosted":"2009-07-16","lastUpdate":"2012-02-02"},"enrollment":760,"design":{"allocation":"RANDOMIZED","model":"PARALLEL","masking":"TRIPLE","primaryPurpose":"TREATMENT"},"conditions":["Gout"],"interventions":[{"type":"DRUG","name":"Febuxostat","otherNames":["TMX-67","Tei-6720","Uloric"]},{"type":"DRUG","name":"Febuxostat","otherNames":["TMX-67","Tei-6720","Uloric"]},{"type":"DRUG","name":"Allopurinol","otherNames":[]}],"arms":[{"label":"Febuxostat 80 mg QD","type":"EXPERIMENTAL"},{"label":"Febuxostat 120 mg QD","type":"EXPERIMENTAL"},{"label":"Allopurinol 300 mg QD","type":"ACTIVE_COMPARATOR"}],"summary":"The purpose of this study is to evaluate the safety and efficacy of febuxostat, once daily (QD), versus allopurinol in subjects with gout.","primaryOutcome":{"measure":"Percentage of Subjects With the Last 3 Serum Urate Levels <6.0 Milligrams Per Deciliter (mg/dL)","timeFrame":"Last 3 Visits (up to 52 weeks)","effectByArm":[{"arm":"Febuxostat 80 mg QD","deltaMin":53,"sd":null},{"arm":"Febuxostat 120 mg QD","deltaMin":62,"sd":null},{"arm":"Allopurinol 300 mg QD","deltaMin":21,"sd":null}],"pValues":[{"comp":"OG000 vs OG002","p":null},{"comp":"OG001 vs OG002","p":null},{"comp":"OG000 vs OG002","p":"<0.001"},{"comp":"OG001 vs OG002","p":"<0.001"},{"comp":"OG000 vs OG001","p":"0.072"}]},"eligibility":{"minAge":"18 Years","sex":"ALL","healthyVolunteers":false,"inclusionCount":2,"exclusionCount":7},"locations":{"siteCount":0,"countries":[]},"refs":{"pmids":["16339094","18600509","21353107","22052584"],"seeAlso":["http://www.rheumatology.org/","http://general.takedapharm.com/content/file.aspx?applicationcode=6C7C39D8-5D09-453B-BF30-696A4AB88E62&fileTypeCode=ULORICPI"]},"adverseEventsSummary":{"seriousAny":{"events":10,"n":256},"commonTop":["Upper Respiratory Tract Infections","Musculoskeletal and Connective Tissue Signs and Symptoms NEC","Joint Related Signs and Symptoms","Diarrhoea (Excl Infective)","Headache NEC"]}}